ACTINIUM PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 284.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-07
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 254.00K shares.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 30.00K shares.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 25.00K shares, a 83.76% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 35.97K shares, a 34826.21% increase year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 61.00K shares, a 60.39% decline from fiscal 2024.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 154.00K shares, a 93.59% decline from fiscal 2023.
- ACTINIUM PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.40M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 254.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | 284.00K shares 10-Q · filed 2026-08-07 | 309.00K shares derived: sum of 3 quarters · filed 2026-08-07 | 344.97K shares derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | 30.00K shares 10-Q · filed 2026-05-08 | 55.00K shares derived: sum of 2 quarters · filed 2026-05-08 | 90.97K shares derived: sum of 3 quarters · filed 2026-05-08 | |
| 2025-12-31 | 25.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 60.97K shares derived: sum of 2 quarters · filed 2026-03-30 | 61.00K shares 10-K · filed 2026-03-30 | |
| 2025-09-30 | 35.97K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 36.00K shares 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | 26.00 shares 10-Q · filed 2025-08-08 | |||
| 2024-12-31 | 153.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 154.00K shares derived: sum of 2 quarters · filed 2026-03-30 | 154.00K shares 10-K · filed 2026-03-30 | |
| 2024-09-30 | 103.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 104.00 shares 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | 1.00 shares 10-Q · filed 2024-08-05 | |||
| 2023-12-31 | 2.40M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 2.40M shares derived: sum of 2 quarters · filed 2025-03-31 | 2.40M shares 10-K · filed 2025-03-31 | |
| 2023-09-30 | -4.83K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 166.00 shares 10-Q · filed 2023-11-02 | ||
| 2023-06-30 | 5.00K shares 10-Q · filed 2023-08-14 | |||
| 2022-09-30 | 1.76K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 1.89K shares 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | 120.00 shares 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | 50.00K shares 10-Q · filed 2021-05-14 | |||
| 2018-03-31 | 387.23K shares 10-Q · filed 2018-05-10 | |||
| 2014-06-30 | 100.00K shares 10-Q · filed 2014-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |